Parent Interventions: As a Studious Girl Destroyed Her Mobile Phone  |  Teacher Insights: Know about how to choose the best MPPSC coaching institute  |  National Edu News: Swinburne University of Technology & IIT H launch the joint doctoral program  |  Policy Indications: India & Japan collaborations for innovations on Hydrogen based technologies  |  National Edu News: Education Minister addresses at the Annual Convocation of IIM Rohtak  |  Education Information: UPSC postpones tests and Interviews of some examinations  |  National Edu News: Piyush Goyal launches the Startup India Seed Fund Scheme  |  Teacher Insights: Are you Proficient in English?  |  National Edu News: National climate vulnerability assessment sees 8 states as highly vulnerable  |  National Edu News: Education minister e-launches long-lasting hygiene product DuroKea Series  |  National Edu News: Punjab’s new nutrient rich crop varieties can satisfy India's nutritional needs   |  Guest Column: Delicious Dhabas  |  International Edu News: 2D Perovskites for Solar Cells and LEDS  |  International Edu News: AI Model for Predicting Tsunami  |  International Edu News: Wearable Sweat Sensors on a Bandage  |  
February 24, 2021 Wednesday 11:46:47 AM IST

Scientists model a peculiar type of breast cancer

Parent Interventions

Scientists led by EPFL have developed a breakthrough in vivo model for invasive lobular carcinoma, a serious yet understudied type of breast cancer. The work will open up previously inaccessible study of the tumor’s biology and help discover new therapies. Invasive lobular carcinoma (ILC) is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast. It covers 10-15% of all breast cancer cases, has a high risk of late recurrence, unique metastatic sites, high sensitivity to hormones, unpredictable responses to therapies, unique histopathology, distinctive biology, and resists chemotherapy. More than 90% of ILC tumors also contain estrogen receptors, meaning that they can receive hormone signals from the body e.g. estradiol, that can spur their growth and metastasis.

Despite all this, ILC is relatively understudied compared to other breast cancers, and as a result, there have been very few models developed to study it. The reason is the lower incidence of ILC in general, but also because ILC tumors don’t lend themselves to growth in culture or in mice, which is key to developing models.

Now, scientists at EPFL’s have successfully overcome the limitations of ILC and have developed a xenograft model for it that simulates the tumor with high accuracy. The scientists, led by EPFL researcher George Sflomos, at the laboratory of Professor Cathrin Brisken grafted two ILC-derived metastatic breast cancer cell lines as well as freshly resected ILC tumors from patients directly into the milk ducts of mice that are immune deficient. The study is now published in EMBO Molecular Medicine.

The approach allowed the researchers to develop a series of in vivo models of lobular breast cancer. It is particularly important that these experimental ILC tumors retain estrogen receptor expression, as well as their responsiveness to estradiol that ILC tumors typically show. “The samples preserve the histomorphological aspects, and the peculiar metastatic patterns of ILC. The findings are particularly important for studying ILC metastasis which is primarily responsible for ILC cancer-related mortality,” says George Sflomos, first author of the study.

The model tumors also revealed some secrets of ILC biology. They appear to have similar peculiarities in the extracellular matrix such as their intrinsic ability to produce elastin, collagens, and the collagen-modifying enzyme LOXL1. So, when the researchers blocked all LOX enzymes, they saw a decrease in primary tumor growth, metastasis, and estrogen receptor signaling.

(Content Courtesy: